Related Experiment Videos
Targeting the chemokine system for multiple sclerosis treatment
1Department of Neurology. Medical University of Lodz, Poland. aglabinski@afazja.am.lodz.pl
Current Opinion in Investigational Drugs (London, England : 2000)
|March 15, 2002
Summary
Chemokines and their receptors are key drivers in multiple sclerosis (MS) pathogenesis. Targeting these chemokine-chemokine-receptor interactions offers a promising therapeutic strategy for MS and other central nervous system inflammatory diseases.
Area of Science:
- Neuroimmunology
- Neuroinflammation
- Demyelinating Diseases
Background:
- Multiple sclerosis (MS) is a primary demyelinating disorder of the central nervous system (CNS).
- Active MS is characterized by inflammatory foci within the CNS.
- Chemokines are believed to dictate the composition of inflammatory infiltrates in these foci.
Purpose of the Study:
- To explore the role of chemokines in MS pathogenesis.
- To evaluate the potential of targeting chemokine-chemokine-receptor interactions for MS treatment.
Main Methods:
- Review of studies investigating chemokine involvement in MS.
- Analysis of therapeutic strategies including neutralizing antibodies, modified chemokine peptides, and small molecule antagonists.
Main Results:
- Chemokine involvement in MS pathogenesis is supported by numerous studies.
- Therapeutic approaches have evolved from neutralizing antibodies to small molecule antagonists.
- Chemokine receptors are identified as promising therapeutic targets.
Conclusions:
- Chemokines and their receptors play a significant role in the inflammatory processes of MS.
- Interfering with chemokine-chemokine-receptor pathways holds potential for preventing and ameliorating CNS inflammation.
- Targeting chemokines and their receptors represents a promising strategy for treating MS and other CNS inflammatory and autoimmune diseases.